Montana will let patients buy drugs that cleared only a safety trial.
Montana's health department finalised regulations for its Experimental Treatment Review Board, the body created under 2025's SB 535 to let patients access drugs that have completed only a Phase I safety trial without full FDA approval. The board is due to review its first applications shortly.
The law creates a real, regulated pathway with a state board, for patients whose options are limited. That's a genuine expansion of choice and worth watching.
Phase I clearance establishes that a drug didn't obviously harm a small group. Most drugs that clear it never show efficacy. Reviewers also flagged a combination the framing doesn't mention: no FDA or ethics-board oversight, legal immunity for providers, and self-set pricing.
Three checks on what Phase I clearance predicts, on whether reviewers found new risk, and on what oversight the law actually pairs with.
Being right about what happened and wrong about what it proves are different failures, so these two lines never get averaged into one score. How this works
The logic check
If the claim is right, these things should be true. Here's what we found. Each check says which version of the claim it's testing, the plain one most people would hear or the widest one the same words could carry, and whether it carries the claim's own burden or establishes the background it sits on.
If Phase I clearance reliably signals a 'miracle cure' as the framing implies, most Phase I-cleared drugs should go on to demonstrate real-world efficacy.
Reading failsThe poster's own follow-up post states only about 5% of therapies that succeed in animal studies eventually gain FDA approval; more broadly, Phase I trials test safety and dosage, not efficacy, and most candidates fail in later trials. source
If the law carries no material new risk as the strongest reading implies, bioethicists reviewing it should not identify a distinct new harm pathway beyond ordinary Phase I risk.
Reading failsNYU bioethicist Alison Bateman-House and other critics flagged the specific combination of no FDA/IRB oversight, broad legal immunity for providers, and self-set pricing, as a new risk pathway distinct from ordinary trial-stage risk. source
If the minimal reading holds (a genuine, bounded patient-choice expansion, not an unqualified miracle-cure pipeline), the law should pair with real oversight and named patients pursuing it in good faith, not run as an unregulated free-for-all.
Reading survivesMontana's law does pair expanded access with a state review board that vets applications, and reporting profiles a specific named family (the DeVaults) pursuing a specific therapy through that board. source
The receipts
Every quote, checked against its source.
Carrier set
"Pretty soon, if you need access to an experimental new drug—say, for your rare type of cancer—then you'll be going to Montana. The treasure state is going to allow Americans to access drugs that passed a phase I trial, making miracle cures accessible long before FDA approval!"
The full scoring
The raw numbers behind the verdict. What R/I/P/E/L and charge stages mean: how we score.
Research verdict: mixed evidence. This is the category the underlying research assigned before we ran the individual checks, and it came back the same on every card in this set.
Montana's clinics moving from statute to operating regulation this week is a real, dated trigger, and the 'FDA as gatekeeper' framing runs into a genuine opposing camp embedded in the same mainstream coverage rather than a strawman. We coded C2: this is early capture on a freshly operational law, not yet a sedimented standing lens the way the Fauci narratives above are. The claim's weakest point, treating Phase I clearance as proof of a cure, does not hold up under an independent check; the underlying access-expansion claim is more defensible.
Source record: hobocode.net Fault Line Report 2026-W31
The Fault Line Report, July 27 to August 2, 2026
All twenty-seven narratives with the full logic test, the mirror check, the R/I/P/E/L factors and the coverage notes on each lane. This page is the plain-language cut; that one is the whole thing, including the polarization methodology that defines every score here.